Amorphical Announces Full Patient Enrollment in Phase 2 FDA Clinical Trial of AMOR-1 for the Treatment of Hypoparathyroidism

Phase 2AMOR-1Positive

AI Analysis

Summary

Amorphical announced full patient enrollment in its Phase 2 FDA clinical trial of AMOR-1 for hypoparathyroidism treatment, a nano-amorphous calcium carbonate technology designed to reduce required elemental calcium dosing compared to conventional therapies.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Full patient enrollment completed

Importance:5/10

Sentiment:

0.60

Phase 2Patient EnrollmentHypoparathyroidismNano-Amorphous TechnologyClinical Trial

Read the original article

Published by PR Newswire Biotech on July 28, 2026 12:30 PM

Read Original